Iraizoz BA, Bataille B, Castanedo CN, Iraizoz CA, Lidwine G, Barrios ÁMA, Baylac G

Language: Spanish
References: 19
Page: 150-161
PDF size: 228.82 Kb.

ABSTRACT

Objective: to increase the solubility of 2-bromium-5(2-bromium-2-nitrovinyl)-furane (G1), one pharmaceutically active ingredient with potent bactericidal and fungicidal action, synthesized through the preparation of solid dispersion macroparticles based on spray-drying process in the Center of Chemical Bioactives of the Central University in Las Villas province.
Methods: a preliminary spray-drying test of GI suspension made up of 10 g of G1, 1g of Aerosil (Aerosil®, Degusa, Bélgica), 1g of sodium laurylsulphate and 100 mL of water was made. A piece of lab equipment known as Buchi Mini Dryer spray served for the spraying at 90 ºC. The solid dispersion was characterized from the physical and chemical viewpoints through X-ray diffraction, laser granulometry based on angular diffraction method, differential scanning calorimetry, electronic scanning microscopy and infrared spectrophotometry.
Results: the obtained particles were small, spherical and had increased G1 crystallinity. No interactions were found in the dispersion components; there were no degradation products, and G1 solubility was significantly increased.
Conclusions: the product obtained from spray-drying technique substantially raised the solubility of G1 without affecting the functional groups, which are responsible for the reported therapeutic action of the studied active ingredient. These encouraging results endorse the need for further studies to optimizing the process and carrying out stability tests for the product to be included in the pharmaceutical forms of dosing in the future.

REFERENCES

1. Wilkarsa S, Durand D, Delarbre JL, Bayllac G, Bataille B. The improvement of Ibuprofen dissolution rate through microparticles spray drying processed in an aqueous system. Drug Develop Ind Pharm. 2008;34:485-91.

2. Bittner B, Mountfield RJ. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Current Opin Drug Discov Develop. 2002;5:59-71.

3. Bittner B, Mountfield RJ. Formulations and related activities for the oral administration of poorly water-soluble compounds in early discovery animal studies. Pharm Ind. 2002;64:800-7.

4. Amidon G, Lennernas H, Shah VP, Crison JR. A Theoretical basis for a biopharmaceutical drug classification, the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-20.

5. FDA Guidance for industry. Waiver of in vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System CDER/FDA. Silver Spring, MD: FDA;2000.

6. Ching-Ling Ch, Laurence XYu, Hwei-Ling L, Chyun-Yu Y, Chang-Sha L, Chen-His Ch. Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur J Pharm Sci. 2004;22:297-304.

7. Noyes AA, Whitney WR. The rate of solution of solid substance in their own solutions. J Am Chem Soc. 1897;19:930-4.

8. Nernst, W. Theorie der reaktionsgeschwindigkeit in heterogenen Sistemen. Zeitschrift F Physik Chemie. 1904;47:52-5.

9. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharma Biopharm. 2000;50:47-60.

10. Branchu S, Rogueda PG, Plumb AP, Cook W.G. A decision-support tool for the formulation of orally active, poorly soluble compounds. Eur J Pharm Sci. 2007;32:128-39.

11. Stegemann S, Leveiller F, Franchi D, de Jong H, Lindén H. When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci. 2007;31:249-61.

12. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29:278-87.

13. Wang X, Michoel A, Van den Mooter G. Solid state characterisation of ternary solid dispersions composed of PVPVA 64, Myrj 64 and itraconazole. Int J Pharm. 2005;303:54-61.

14. Six K, Leuner C, Dressman JB, Verreck G, Peeters J, Blaton N, et al. Thermal properties of hot-stage extrudates of itraconazole and Eudragit E100, phase separation and polymorphism. J Therm An Cal. 2002;68:591-601.

15. Broman E, Khoo C, Taylor LS. A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water soluble drug. Int J Pharm. 2001;222:139-51.

16. Janssens S, Anné M, Rombaut P, Van den Mooter G. Spray drying from complex solvent systems broadens the applicability of Kollicoat IR as a carrier in the formulation of solid dispersions. Eur J Pharm Sci. 2009;37:241-8.

17. Kawakami K, Oda N, Miyoshi K, Funaki T, Ida Y. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents. Eur J Pharm Sci. 2006;28:7-14.

18. Chauhan B, Shimpi S, Paradkar A. Preparation and evaluation of glibenclamidepolyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique. Eur J Pharm Sci. 2005;26:219-30.

19. Kim EJ, Chun MK, Jang JS, Lee IH, Lee KR, Choi HK. Preparation of a solid dispersion of felodifine using a solvent wetting method. Eur J Pharm Biopharm. 2006;64:200-5.